IAVI C003

Status:Completed

Phase:I

Principal Investigator(s):

Objective:A study to evaluate the safety and immunogenicity of a single dose of MVA expressing HIV-1 clade C env/gag-pol and nef-tat fusion genes (ADMVA).

Prevention Option(s):HIV Vaccine

Study Design:

Arms and Assigned Interventions

DescriptionADMVA administered to volunteers who previously received three doses of a clade C DNA Vaccine ADVAX e/g + ADVAX p/n-t

Mode of DeliveryIntramuscular

ARMsExperimental

Official Code: IAVI C003

Trial Sponsors: Aaron Diamond AIDS Research Center, University of Rochester Medical Center

Start Date

End Date

none

Enrollment:8

Age range: ↔ any

Population:

Stay up-to-date!